Press releases
These press releases are intended for journalists and analysts/investors.
-
Global survey finds parents need to short-circuit their own anxiety to better manage their child’s illness
Global survey finds parents need to short-circuit their own anxiety to better manage their child’s illness
-
A shot in the arm for a shot at gold
The Australian Women’s Football team received travel vaccinations free of charge as part of an agreement between GSK and the Australian
-
Bactroban (mupirocin) 2% Ointment supply
Following manufacturing issues, supply of Bactroban (mupirocin) 2% Ointment for the topical treatment of mild impetigo
-
Easier access to medicines for men with enlarged prostates following medicine reimbursement changes
Australian men with an enlarged prostate are set to benefit from changes to the Pharmaceutical Benefits Scheme (PBS) which now allows
-
Supply of Zovirax Ophthalmic Ointment (aciclovir 3%) resumes
Resumed supply of Zovirax Ophthalmic Ointment confirmed following a global supply shortage
-
Product Recall - Children's Panadol
Providing quality products and consumer safety are always our top priority and we want to ensure that consumers only have access
-
GSK Australia Reports 2015 results to ASIC
GlaxoSmithKline (GSK) Australia has reported its 2015 results to the Australian Securities and Investment Commission (ASIC)
-
Supply of Bactroban products
GSK advises of a temporary disruption to the supply of Bactroban Cream (mupirocin calcium cream, 2% w/w), Bactroban Ointment and Bactroban
-
GSK discloses payments to Australian healthcare professionals in 2015
In 2015, GSK Australia made payments totalling $3.6 million to healthcare professionals (HCPs) and health-related organisations (HCOs)
-
GSK supports National Immunisation Program (NIP) with additional whooping cough protection via an 18-month dose on the NIP
GSK Australia is proud to be partnering with the Australian Government to re-introduce a diphtheria, tetanus, acellular pertussis (DTPa)
-
Whooping cough vaccines update
Additional whooping cough booster at 18-months on the NIP
-
Australia leads the world in body pain blues
New research shows that 97 percent of Australians suffer from body aches, with a massive two thirds (68%) experiencing it at least weekly
-
GSK establishes Immunology Network to collaborate with academic research scientists
Global pharmaceutical company, GSK has launched a new immunology research collaboration model
-
Boostrix availability
GSK prioritises whooping cough vaccine availability for those most at risk of the disease and confirms uninterrupted supply of Boostrix®
-
GSK first in Australia with new business model for the pharmaceutical industry
The changes represent a fundamental shift in the GSK business model and will come into effect in Australia for 2016
-
Australian manufacturing innovation starts pilot with the hope it could reduce cost of vaccination in developing world
GSK Australia today opened a new pilot vaccine facility at its Boronia site to manufacture a vaccine testing a new production method
-
Amgen reacquires all rights to Prolia® (denosumab) in Australia
Amgen and GSK to Work Together to Ensure a Smooth Transition for Prolia® Patients and Their Physicians
-
Winning research team unlocks immune system secret - specialised T cells attack microbes as they make their vitamins
A research partnership between The University of Melbourne and Monash University has won $80,000 to help continue groundbreaking work
-
GSK supports National Immunisation Program with four strain flu vaccine for 2016
GSK Australia is proud to be partnering with the Australian Government to provide a quadrivalent (four-strain) influenza vaccine
-
Research shows 53 per cent of Australians never consult a GP for hay fever advice
New consumer research[1] shows one in two (53%) Australians with hay fever have never sought advice from their GP to manage their symptoms
